View clinical trials related to Gambling.
Filter by:This study is divided into two stages. The first stage is a transversal study and corresponds to the recruitment of participants, which will last about two years. Three groups of gamblers will be constituted : Non-problematic gamblers (NPG), Problematic gamblers Not in Care (PGNC) and Problematic gamblers in Care (PGC).The second stage is a prospective 5-year follow-up study of the cohort (only the initial NPG and PGNC groups are concerned by the follow-up study), that consists on an annual follow-up evaluation. The main objective of the first stage of the study is to compare the characteristics of the three groups of gamblers on some socio-demographic and clinical data. These comparisons will allow us to identify, among all data, those that will be most likely to explain the evolution of the practice of gambling (appearance or resolution of a gambling problem), and recourse to specific care. These such isolated data will be tested in the second stage of the study, in order to determine those that are predictive factors of three steps of the gambling course of some gamblers : evolution of a controlled gambling practice into a problematic gambling practice, resolution of the problematic gambling practice without intervention of care, and first recourse to specific care.
The investigators plan to investigate the safety, tolerability, and efficacy of the opioid antagonist naltrexone in Pathological Gambling. We hypothesize that naltrexone will be superior to placebo in reducing gambling urges and behavior, when combined with adjuvant non-pharmacological treatment as usual.
The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and pathological gamblers (PG) symptoms in nicotine dependent pathological gamblers.
The goal of the proposed study is to evaluate the efficacy and safety of tolcapone in pathological gambling.
Pathological gambling is serious problem, with significant psychological, financial, and public health consequences. Nevertheless, controlled trials examining the efficacy of therapeutic interventions for pathological gamblers are sparse, and many pathological gamblers recover on their own, or with only minimal interventions. In this initial study of a SMART design for pathological gamblers, we will offer a brief intervention to all (n = 100), and subsequently randomize individuals based upon their initial treatment response to varying intensities of additional care from none to 8 sessions of individual cognitive behavioral therapy (CBT) plus 14 weeks of Aftercare. Gambling outcomes will be assessed pre-treatment and at about weeks 10, 24, 36 and 52.
This project evaluates the efficacy of brief interventions for individuals seeking treatment for substance use disorders who also have gambling problems. In total, 220 problem gambling substance abusers will be randomized to one of three conditions: (a) a control condition consisting of 10 minutes of psychoeducation about gambling, (b) 10 minutes of brief advice about problem gambling and how to reduce it, or (c) four session of motivational and cognitive-behavioral therapy. Gambling, substance use and psychosocial problems will be assessed using standardized instruments at pre-treatment, month 2, 5, 8, 12, 16, 20 and 24-month follow-up evaluations.
This study will determine the effectiveness of three different treatment strategies in reducing gambling behaviors in pathological gamblers.
The goal of the proposed study is to evaluate the efficacy and safety of the drug memantine in individuals with pathological gambling (PG). Thirty subjects with DSM-IV PG will receive 10 weeks of open-label treatment with memantine. The hypothesis to be tested is that memantine will be effective and well tolerated in patients with PG. We hypothesize that memantine will reduce the severity of gambling symptoms and improve patients' overall functioning. This study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.
The purpose of the this study is to compare pathological gamblers versus non-pathological gamblers using tests that measure different components of impulsivity. We aim to invite a total of 120 individuals to participate in this study. Impulsivity has been described as the cognitive inability to delay gratification, a failure to inhibit behavioral action or acting without forethought about consequences. Impulsivity has also been seen as a personality trait characterized by risk-taking or sensation seeking behavior. Pathological gamblers demonstrate aspects of impulsivity; they act without thinking, have difficult inhibiting urges to gamble and desire immediate gratification. The goal of this project is to clarify which components of impulsivity are associated with pathological gambling. Non-treatment seeking, pathological gamblers and controls will be recruited from the community and local casinos. Each participant will be administered a battery of tests that represent different operational definitions of impulsivity.
The main aim of this randomized controlled trial is to evaluate the sustained efficacy of a personalized feedback intervention for problem gamblers. Adult problem gamblers who express an interest in self-help materials for gamblers will be recruited from respondents to a random digit telephone survey, which also collects the baseline data. Subjects will be randomly assigned to receive personalized feedback about their gambling, or to a waiting list control group. Three-month, six-month, and 12-month follow-up surveys will be conducted by mail to assess gambling over the intervening periods. Collaterals will be requested as part of the 12-month follow-up and interviewed by telephone. Gambling at three- six- and 12-months will be compared between the groups. Change in perception of gambling norms and sex will be tested as mediational and moderating variables.